Company / Return on Assets (ROA)
Janux Therapeutics, Inc. Return on Assets (ROA) History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
-11.3%
FY2025
5-year range
-17.3% / -6.5%
FY2021-FY2025
Trend
-74.5%
vs FY2024
Sector context
#85 of 213
Health Care
What the data says
At -11.3%, Janux Therapeutics, Inc.'s return on assets (roa) ranks #85 of 213 in the Health Care sector. Return on Assets (ROA) has fluctuated over the past 6 years, ranging from -41.8% in FY2020 to -6.5% in FY2024.
Based on SEC 10-K filings.
-11.3% in FY2025 with a 5-year CAGR of +30.5%.
Improved from -15.3% to -11.3% over the past 2 years.
Health Care sector context is included.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- +6.0pp
- 5-Year Change
- +30.5pp
- 10-Year Change
- -
Sector benchmark
#85 of 213 in Health CareTop 40% of 213This company -11.3% Sector average -24.1%
▼
+52.9% above sector average
Key checks
Key Insights
- In FY2025, return on assets (roa) decreased 74.5% year-over-year.
- Currently 12.7pp above the Health Care sector average.
- Peak return on assets (roa) was recorded in FY2024.
- Lowest return on assets (roa) in the period was in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 9.17 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -11.3% | -74.5% |
| FY2024 | -6.5% | +57.6% |
| FY2023 | -15.3% | +11.5% |
| FY2022 | -17.3% | -101.4% |
| FY2021 | -8.6% | +79.4% |
| FY2020 | -41.8% | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026